A recent article in Nature Immunology underscores the critical role of chronic inflammation in the development and persistence of long COVID. This insight builds upon multiple credible scientific studies that consistently demonstrate sustained inflammatory responses and immune system dysregulation in individuals experiencing post-acute sequelae of SARS-CoV-2 infection (PASC). Research indicates that long COVID patients exhibit persistent activation of various inflammatory immune pathways, including IL-6 signaling, JAK–STAT signaling, and complement activation, which can endure for over 180 days after the initial infection. Concurrently, markers of T cell activation are reduced, while signs of T cell exhaustion are increased, suggesting that prolonged immune stimulation impairs normal immune function. Notably, studies have largely found no evidence of ongoing viral replication in long COVID patients, pointing to immune dysregulation rather than a lingering infection as the primary driver of persistent symptoms. The findings also highlight that heightened inflammatory responses during the acute phase of COVID-19 can predict who will subsequently develop long COVID, suggesting the potential for early immune biomarkers to identify at-risk individuals. This deepened understanding of the underlying mechanisms is pivotal, as it opens doors for novel therapeutic approaches. Specifically, targeting inflammatory pathways with immunomodulatory drugs, such as the JAK1 inhibitor abrocitinib, is now being explored in clinical trials. Globally, long COVID remains a significant public health challenge, affecting millions. In India, research has reported a high prevalence of long COVID, with nearly 40% of recovered individuals in some regions experiencing symptoms like fatigue, dyspnea, myalgia, and cognitive dysfunction beyond 12 weeks. The burden is further compounded by its impact on mental health and the deepening of socioeconomic inequalities, particularly for marginalized workers. The identification of distinct patterns of inflammation provides a foundation for developing targeted diagnostic tools and personalized treatments, moving beyond a one-size-fits-all approach.